Advertisement
Screener

IMMUNITYBIO, INC. (IBRX) Increase (Decrease) in Other Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

IMMUNITYBIO, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities

IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $11.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-04

  • IMMUNITYBIO, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $8.56M, a 1.83% decline year-over-year.
  • IMMUNITYBIO, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $3.14M.
  • IMMUNITYBIO, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.93M.
  • IMMUNITYBIO, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $5.47M, a 12.16% decline year-over-year.
  • IMMUNITYBIO, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $3.18M.
  • IMMUNITYBIO, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was -$1.51M, a 122.54% decline from fiscal 2023.
  • IMMUNITYBIO, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $6.69M, a 63.07% increase from fiscal 2022.
  • IMMUNITYBIO, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $4.10M, a 20.84% decline from fiscal 2021.
Period endIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month as first filedIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month as first filedIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month as first filedIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 12 monthIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month as first filed
2026-06-30$8.56M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$11.70M
10-Q · filed 2026-08-04
$13.63M
derived: sum of 3 quarters · filed 2026-08-04
$19.09M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$3.14M
10-Q · filed 2026-05-07
$5.06M
derived: sum of 2 quarters · filed 2026-05-07
$10.53M
derived: sum of 3 quarters · filed 2026-05-07
$19.25M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
$7.39M
derived: sum of 2 quarters · filed 2026-02-23
$16.12M
derived: sum of 3 quarters · filed 2026-08-04
$3.18M
10-K · filed 2026-02-23
2025-09-30$5.47M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$14.19M
derived: sum of 2 quarters · filed 2026-08-04
$1.26M
10-Q · filed 2025-11-05
-$855.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$8.72M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$4.21M
10-Q · filed 2026-08-04
-$6.32M
derived: sum of 3 quarters · filed 2026-08-04
-$98.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$12.93M
10-Q · filed 2026-05-07
-$15.05M
derived: sum of 2 quarters · filed 2026-05-07
-$8.82M
derived: sum of 3 quarters · filed 2026-05-07
-$5.52M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$2.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
$4.11M
derived: sum of 2 quarters · filed 2026-02-23
$7.41M
derived: sum of 3 quarters · filed 2026-02-23
-$1.51M
10-K · filed 2026-02-23
2024-09-30$6.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$9.52M
derived: sum of 2 quarters · filed 2025-11-05
$606.00K
10-Q · filed 2025-11-05
-$18.91M
derived: sum of 4 quarters · filed 2026-02-23
2024-06-30$3.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$5.62M
10-Q · filed 2025-08-05
-$25.14M
derived: sum of 3 quarters · filed 2026-02-23
-$26.80M
derived: sum of 4 quarters · filed 2026-02-23
2024-03-31-$8.92M
10-Q · filed 2025-05-12
-$28.43M
derived: sum of 2 quarters · filed 2026-02-23
-$30.09M
derived: sum of 3 quarters · filed 2026-02-23
-$20.82M
derived: sum of 4 quarters · filed 2026-02-23
2023-12-31-$19.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$21.18M
derived: sum of 2 quarters · filed 2026-02-23
-$11.90M
derived: sum of 3 quarters · filed 2026-02-23
$6.69M
10-K · filed 2026-02-23
2023-09-30-$1.66M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$7.62M
derived: sum of 2 quarters · filed 2024-11-12
$26.20M
10-Q · filed 2024-11-12
$23.05M
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30$9.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$27.86M
10-Q · filed 2024-08-12
$24.71M
derived: sum of 3 quarters · filed 2025-03-03
$31.36M
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31$18.59M
10-Q · filed 2024-05-09
$15.44M
derived: sum of 2 quarters · filed 2025-03-03
$22.09M
derived: sum of 3 quarters · filed 2025-03-03
$11.80M
derived: sum of 4 quarters · filed 2025-03-03
2022-12-31-$3.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$3.50M
derived: sum of 2 quarters · filed 2025-03-03
-$6.79M
derived: sum of 3 quarters · filed 2025-03-03
$4.10M
10-K · filed 2025-03-03
2022-09-30$6.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$3.64M
derived: sum of 2 quarters · filed 2023-11-09
$7.25M
10-Q · filed 2023-11-09
$11.81M
derived: sum of 4 quarters · filed 2024-03-19
2022-06-30-$10.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$602.00K
10-Q · filed 2023-08-08
$5.16M
derived: sum of 3 quarters · filed 2024-03-19
$9.61M
derived: sum of 4 quarters · filed 2024-03-19
2022-03-31$10.89M
10-Q · filed 2023-05-11
$15.45M
derived: sum of 2 quarters · filed 2024-03-19
$19.89M
derived: sum of 3 quarters · filed 2024-03-19
$17.97M
derived: sum of 4 quarters · filed 2024-03-19
2021-12-31$4.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
$9.00M
derived: sum of 2 quarters · filed 2024-03-19
$7.08M
derived: sum of 3 quarters · filed 2024-03-19
$5.18M
10-K · filed 2024-03-19
2021-09-30$4.45M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$2.52M
derived: sum of 2 quarters · filed 2022-11-09
$624.00K
10-Q · filed 2022-11-09
$1.96M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30-$1.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$3.82M
10-Q · filed 2022-08-08
-$2.48M
derived: sum of 3 quarters · filed 2023-03-01
-$1.54M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31-$1.89M
10-Q · filed 2022-05-10
-$556.00K
derived: sum of 2 quarters · filed 2023-03-01
$386.00K
derived: sum of 3 quarters · filed 2023-03-01
$2.37M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$1.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$2.28M
derived: sum of 2 quarters · filed 2023-03-01
$4.27M
derived: sum of 3 quarters · filed 2023-03-01
$12.49M
10-K · filed 2023-03-01
$3.69M
10-K · filed 2021-03-04
2020-09-30$942.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$2.93M
derived: sum of 2 quarters · filed 2021-11-12
$11.16M
10-Q · filed 2021-11-12
$1.57M
10-Q · filed 2020-11-09
$10.98M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$1.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$10.22M
10-Q · filed 2021-08-12
$1.47M
10-Q · filed 2020-08-07
$10.04M
derived: sum of 3 quarters · filed 2022-03-01
$10.88M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$8.23M
10-Q · filed 2021-05-14
$997.00K
10-Q · filed 2020-05-11
$8.05M
derived: sum of 2 quarters · filed 2022-03-01
$8.90M
derived: sum of 3 quarters · filed 2022-03-01
-$4.37M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31-$174.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$669.00K
derived: sum of 2 quarters · filed 2022-03-01
-$12.59M
derived: sum of 3 quarters · filed 2022-03-01
-$11.80M
10-K · filed 2022-03-01
-$12.02M
10-K · filed 2020-03-25
2019-09-30$843.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$12.42M
derived: sum of 2 quarters · filed 2020-11-09
-$11.62M
10-Q · filed 2020-11-09
-$13.53M
derived: sum of 4 quarters · filed 2021-03-04
2019-06-30-$13.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
-$12.46M
10-Q · filed 2020-08-07
-$14.38M
derived: sum of 3 quarters · filed 2021-03-04
-$360.00K
derived: sum of 4 quarters · filed 2021-03-04
2019-03-31$797.00K
10-Q · filed 2020-05-11
-$1.11M
derived: sum of 2 quarters · filed 2021-03-04
$12.90M
derived: sum of 3 quarters · filed 2021-03-04
$11.63M
derived: sum of 4 quarters · filed 2021-03-04
2018-12-31-$1.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04
$12.11M
derived: sum of 2 quarters · filed 2021-03-04
$10.83M
derived: sum of 3 quarters · filed 2021-03-04
$12.71M
10-K · filed 2021-03-04
2018-09-30$14.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$12.74M
derived: sum of 2 quarters · filed 2018-11-07
$14.62M
10-Q · filed 2018-11-07
$14.77M
derived: sum of 4 quarters · filed 2020-03-25
2018-06-30-$1.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06
$603.00K
10-Q · filed 2018-08-06
$750.00K
derived: sum of 3 quarters · filed 2020-03-25
$1.41M
derived: sum of 4 quarters · filed 2020-03-25
2018-03-31$1.88M
10-Q · filed 2019-05-08
$2.02M
derived: sum of 2 quarters · filed 2020-03-25
$2.68M
derived: sum of 3 quarters · filed 2020-03-25
$1.15M
derived: sum of 4 quarters · filed 2020-03-25
2017-12-31$147.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25
$805.00K
derived: sum of 2 quarters · filed 2020-03-25
-$733.00K
derived: sum of 3 quarters · filed 2020-03-25
-$299.00K
10-K · filed 2020-03-25
2017-09-30$658.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$880.00K
derived: sum of 2 quarters · filed 2018-11-07
-$446.00K
10-Q · filed 2018-11-07
-$773.00K
derived: sum of 4 quarters · filed 2019-03-13
2017-06-30-$1.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06
-$1.10M
10-Q · filed 2018-08-06
-$1.43M
derived: sum of 3 quarters · filed 2019-03-13
-$615.00K
derived: sum of 4 quarters · filed 2019-03-13
2017-03-31$434.00K
10-Q · filed 2018-05-07
$107.00K
derived: sum of 2 quarters · filed 2019-03-13
$923.00K
derived: sum of 3 quarters · filed 2019-03-13
$1.32M
derived: sum of 4 quarters · filed 2019-03-13
2016-12-31-$327.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13
$489.00K
derived: sum of 2 quarters · filed 2019-03-13
$891.00K
derived: sum of 3 quarters · filed 2019-03-13
$2.13M
10-K · filed 2019-03-13
2016-09-30$816.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$1.22M
derived: sum of 2 quarters · filed 2017-11-07
$2.45M
10-Q · filed 2017-11-07
$3.46M
derived: sum of 4 quarters · filed 2018-03-12
2016-06-30$402.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
$1.64M
10-Q · filed 2017-08-07
$2.65M
derived: sum of 3 quarters · filed 2018-03-12
$1.32M
derived: sum of 4 quarters · filed 2018-03-12
2016-03-31$1.24M
10-Q · filed 2017-05-08
$2.24M
derived: sum of 2 quarters · filed 2018-03-12
$915.00K
derived: sum of 3 quarters · filed 2018-03-12
$3.23M
derived: sum of 4 quarters · filed 2018-03-12
2015-12-31$1.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
-$321.00K
derived: sum of 2 quarters · filed 2018-03-12
$1.99M
derived: sum of 3 quarters · filed 2018-03-12
$1.99M
10-K · filed 2018-03-12
2015-09-30-$1.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
$987.00K
derived: sum of 2 quarters · filed 2016-11-10
$984.00K
10-Q · filed 2016-11-10
2015-06-30$2.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15
$2.31M
10-Q · filed 2016-08-15
2015-03-31-$3.00K
10-Q · filed 2016-05-16
2014-12-31-$314.00K
10-K · filed 2017-03-15
2013-12-31$309.00K
10-K · filed 2016-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
Immunovant, Inc. (IMVT)United States$7.028B-14.78
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CRISPR Therapeutics AG (CRSP)$5.390B-11.68